General News of Thursday, 15 April 2021Source: www.ghanaweb.comCountries across the globe are halting the procurement, distribution and deployment of the Oxford-AstraZeneca COVID-19 vaccines citing blood clotting concerns as a side effect. So far, some European countries like Germany, France and Spain have temporarily suspended or halted administering shots for the Oxford-AstraZeneca vaccine. The latest from the batch is the African Union’s Center for Disease Control (CDC) announcing it has dropped plans to secure AstraZeneca COVID-19 vaccines for its member countries. According to health experts, the Oxford-AstraZeneca vaccine has an overall efficacy rate of 76 percent by the time the two required doses are administered. The second dose of the Oxford-AstraZeneca vaccine however is expected to be administered 12 weeks [3 months] later following the first.

Source: GhanaWeb April 15, 2021 12:13 UTC